Biomarker: | MYC overexpression + BCL2 overexpression |
---|---|
Cancer: | Diffuse Large B Cell Lymphoma |
Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + luxeptinib (CG-806) (BTK inhibitor, FLT3 inhibitor, Myeloid kinome inhibitor, Lymphoid kinome inhibitor) |
Direction: | Sensitive |